Ascentage Pharma Group International American Depository Shares (AAPG)
Nasdaq: AAPG · Pharmaceutical Preparations · Suzhou , Jiangsu, CN · filing with the SEC since 2024
Income statement, as filed
In thousands of Chinese yuan (CNY), as filed; per-share figures in Chinese yuan; share counts. The fiscal year ends in December.The Form 20-F filed Apr 29, 2026 for the period ended Dec 31, 2025 is not in EDGAR's company facts yet; its figures here are that filing's own, read from the SEC's financial statement data sets.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Apr 29, 2026 | Apr 16, 2025 | · | · |
| Revenue | 574,120 | 980,650 | 221,984 | 209,711 |
| Cost of revenue | 48,938 | 29,085 | 30,543 | 21,998 |
| Gross profit | 525,182 | 951,565 | 191,441 | 187,713 |
| Research and development | 1,137,448 | 947,245 | 706,972 | 743,104 |
| Sales and marketing | 353,640 | 195,998 | 195,387 | 157,421 |
| General and administrative | 246,281 | 187,125 | 181,076 | 170,595 |
| Finance costs | 54,070 | 64,455 | 96,057 | 52,785 |
| Share of profit of equity-method investments | 314 | -281 | 1,076 | -278 |
| Other gains and losses | · | 1,428 | 2,702 | 2,146 |
| Income before income taxes | -1,236,047 | -395,255 | -932,862 | -887,172 |
| Income tax expense | 6,940 | 10,425 | -7,150 | -4,248 |
| Net income | -1,242,987 | -405,680 | -925,712 | -882,924 |
| Net income to non-controlling interests | -218 | -247 | -75 | · |
| Net income to shareholders | -1,242,769 | -405,433 | -925,637 | -882,924 |
| Earnings per share, basic | -3.49 | -1.34 | -3.28 | -3.35 |
| Earnings per share, diluted | -3.49 | -1.34 | -3.28 | -3.35 |
| Weighted average shares, basic | · | 302,062,104 | 282,299,269 | 263,688,827 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
ifrs-full:RevenueCost of revenue what it cost to make or buy what it sold
ifrs-full:CostOfSalesGross profit revenue less the cost of what it sold
ifrs-full:GrossProfitResearch and development spent on inventing what it sells next
ifrs-full:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
ifrs-full:SellingExpenseGeneral and administrative the cost of running the company itself
ifrs-full:AdministrativeExpenseFinance costs what its borrowing cost
ifrs-full:FinanceCostsShare of profit of equity-method investments its share of companies it partly owns
ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodOther gains and losses gains and costs outside the business
ifrs-full:OtherGainsLossesIncome before income taxes profit before tax
ifrs-full:ProfitLossBeforeTaxIncome tax expense tax charged on the period's profit
ifrs-full:IncomeTaxExpenseContinuingOperationsNet income the whole group's profit, minority holders' share included
ifrs-full:ProfitLossNet income to non-controlling interests the share that belongs to minority holders
ifrs-full:ProfitLossAttributableToNoncontrollingInterestsNet income to shareholders the profit or loss that belongs to the company's shareholders
ifrs-full:ProfitLossAttributableToOwnersOfParentEarnings per share, basic net income per share outstanding
ifrs-full:BasicEarningsLossPerShareEarnings per share, diluted net income per share, counting every share that could be issued
ifrs-full:DilutedEarningsLossPerShareWeighted average shares, basic the average count of shares outstanding
ifrs-full:WeightedAverageShares